Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.30 |
| ▸ | DPYD | Q12882 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512148 | 1.00 | CYP3A4 (0.44) | CYP3A4ALDH1A1LMNABRD4CREBBP | |
| SCHEMBL6832449 | 0.87 | CYP19A1 (0.38) | ALDH1A1LMNABRD4CREBBPDPYD | |
| SCHEMBL2745819 | 0.84 | CYP3A4 (0.43) | CYP3A4BRD4CREBBP | |
| SCHEMBL2745821 | 0.84 | CYP3A4 (0.43) | CYP3A4BRD4CREBBP | |
| SCHEMBL2111449 | 0.78 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL2111450 | 0.78 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL482574 | 0.75 | CYP3A4 (0.75) | CYP3A4ALDH1A1LMNADPYD | |
| SCHEMBL482573 | 0.75 | CYP3A4 (0.75) | CYP3A4ALDH1A1LMNADPYD | |
| SCHEMBL28545623 | 0.75 | DYRK1B (0.42) | ALDH1A1LMNA | |
| SCHEMBL2520555 | 0.75 | CYP3A4 (0.51) | CYP3A4ALDH1A1LMNADPYD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | claimed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP3A4 978/4885ALDH1A1 938/4885LMNA 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.